Friday, August 25, 2023 9:18:47 AM
According to one legal analysis," Instead, the SEC has said that it is up to you, the issuers, other obligated persons and industry professionals, to assess your disclosure obligations and decide what is material and when disclosure is necessary."
I consider myself a reasonable investor - the total mix I want to see in the TLD PR include primary endpoint analysis and important safety information. I expect to see enough analysis information to inform an investment decision - I need to decide if the results are positive or negative to decide whether I will buy or enlarge a position or sell/reduce one. Some details of the analysis are needed as CEOs are legally allowed to bend their statements and to hype related data. I expect to see n, I expect to see the method of the statistical analysis and would like to see imputation method mentioned. Maybe it's just me but that
Years ago, I felt that good or bad news should rapidly be reported for phase 2 and 3 studies after data is analyzed enough to report the documented topline data (primary and key outcomes and key safety) However, I have learned that companies can pretty much disclose what and when they want. The SEC does not police clinical data materiality with the level of aggressiveness they use for financial materiality. CEO's can't outright lie but the SEC has never prosecuted a CEO for partial disclosure of study results or switching endpoints. Missling has misled about results, Missling has released incomplete data but he has stayed on the legal side of the line. He has not misrepresented financial statements so the SEC will not get involved. I have lost respect for him (and by extension AVXL) but have never called for jail time. Regulatory results/outcomes are different than Clinical results outcomes --- a CEO better rapidly report a CRL and should report whether an NDA is accepted (which sets the PDUFA date). They are free to keep internal any FDA communications to help guide studies and when an NDA is submitted. Maybe Missling just does not think that any of us are reasonable investors. He doesn't seem to hold current or potential future shareholders in high regards.
Materiality also can mean different things to different companies. I think missing an endpoint for a 800MM dollar company with one drug in advanced studies is a big deal and should be part of the 'total mix' . Maybe if AVXL was a 100B company with 20 active drugs in the pipeline, missing a 2/3 endpoint would not be material. Not reporting the actual primary endpoint of ADCS-ADL change in mean and switching to a related endpoint (OR) further down in the SAP statistical hierarchy is sleazy but with careful choice of words in the PR, not illegal. It was sleazy enough for me to reduce my position considerably. No one is going to jail but reputation takes a deserved hit.
If Boi or Steady actually have references that state there is asymmetric materiality (bad news must report, good news up to company) please post a link and not just an opinion. I looked and found none. Is it logical to report "good" news o an affiliation with an AI marketing firm but neglect good news from a study that could lead to billions in revenues?
Just for kicks I looked at Lilly that had a large PDD phase 2 study(LY3154207) same time as AVXL PDD trial. The study failed. Lilly never had a PR. There was a void and then data showed up on clinicaltrials.gov about a year later and a peer reviewed article last year. So bad news - no PR - no one goes to jail. https://pubmed.ncbi.nlm.nih.gov/34859493/
Couple nice links to materaility
https://www.mcneeslaw.com/what-is-material-the-sec-says-you-decide/
TSC vs Nothway page 426 US449
https://supreme.justia.com/cases/federal/us/485/224/" rel="nofollow" target="_blank" >https://supreme.justia.com/cases/federal/us/485/224/[tagBasic vs. Levinson[/tag]
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM